Xu, Wanchun, Yan, Vincent Ka Chun, Zhang, Zhijuan, Fung, Kwun Kei, Chan, Koon Ho, Lau, Kui Kai, Chui, Celine Sze Ling, Lai, Francisco Tsz Tsun, Chan, Esther Wai Yin, Li, Xue, Wong, Ian Chi Kei and Wan, Eric Yuk Fai (2024). Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study. Nature Communications, 15 (1),
Abstract
Several international pharmacovigilance agencies have issued warnings regarding the potential risk of myasthenia gravis (MG) following statin therapy. Our study investigated this association using population-based electronic health records in Hong Kong. We conducted a sequence of target trial emulation (TTE) for interpersonal comparison and a self-controlled case series (SCCS) study for intrapersonal comparison. In the TTE for MG onset, the incidence rates (per 100,000 person-years) and adjusted HRs were 51.91(31.80, 84.74)[HR:6.11 (3.73, 10.01)] in month 1, 16.27(9.81, 26.99)[HR:1.92(1.15, 3.19) in months 2-4, and 15.27(9.05, 25.79)[HR:1.80(1.06, 3.04)] in months 5–7. For risk of exacerbation, the adjusted HRs were 10.69(5.48, 20.84) in month 1, 1.50(0.55, 4.06) in months 2–4, and 2.79(1.33, 5.84) in months 5–7. No increased risks were found during the subsequent 18 months. A similar pattern was observed in SCCS analysis. Our findings recommend a minimum monitoring period of approximately six months for MG symptoms for patients starting using statin.
| Publication DOI: | https://doi.org/10.1038/s41467-024-54097-1 |
|---|---|
| Divisions: | College of Health & Life Sciences > Aston Pharmacy School |
| Funding Information: | This study was supported by the National Natural Science Foundation of China (NSFC) Excellent Young Scientists Fund (Hong Kong and Macau) (No. 82222902; E.Y.F.W.). The funders had no role in study design, data collection, data analysis, and data interpret |
| Additional Information: | Copyright © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https:// creativecommons.org/licenses/by-nc-nd/4.0/ |
| Publication ISSN: | 2041-1723 |
| Last Modified: | 31 Mar 2025 07:27 |
| Date Deposited: | 09 Dec 2024 16:05 |
| Full Text Link: | |
| Related URLs: |
https://www.nat ... 467-024-54097-1
(Publisher URL) http://www.scop ... tnerID=8YFLogxK (Scopus URL) |
PURE Output Type: | Article |
| Published Date: | 2024-12 |
| Published Online Date: | 2024-11-28 |
| Accepted Date: | 2024-10-31 |
| Authors: |
Xu, Wanchun
Yan, Vincent Ka Chun Zhang, Zhijuan Fung, Kwun Kei Chan, Koon Ho Lau, Kui Kai Chui, Celine Sze Ling Lai, Francisco Tsz Tsun Chan, Esther Wai Yin Li, Xue Wong, Ian Chi Kei ( 
0000-0001-8242-0014)
Wan, Eric Yuk Fai |
Download
Version: Published Version
License: Creative Commons Attribution Non-commercial No Derivatives
| Preview